Solventum to Spin Off Healthcare Software Unit, Lifts Profit Outlook
SOLV sits 45% above its 52-week low of $62.38.
Summary
Solventum plans to separate its health information systems business, a unit that contributed 16.3% of 2025 sales, as part of a turnaround strategy. The move follows pressure from Trian Fund Management in May to shed non-core assets. The company also raised its 2026 adjusted EPS guidance to $7.10-$7.20, well above the prior $6.40-$6.60, and tightened organic sales growth to 2.5%-3%. Q2 adjusted EPS of $2.55 beat estimates by $0.64, with revenue of $2.21B also ahead. The separation aims to create a more focused MedSurg and Dental Solutions company, potentially unlocking value. The stock is trading near a 52-week high, reflecting strong momentum.
At the time of this announcement, SOLV was trading at $90.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $15.1B. The 52-week trading range was $62.38 to $88.65. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.